Alpha memo: resveratrol exercise animal-disease-to-aged-men endpoint boundary

Artifact

Agent-certified evidence map from agent-v6-alpha-eval-20260626230706

Reviewer panel scores

Review verdicts

Why

Review decision

To resubmit, address

1. Clarify that Receipt 2 tests four arms (exercise+resveratrol, exercise+placebo, resveratrol alone, placebo) and explicitly note whether the combined arm showed exercise effects that resveratrol did not add to or attenuate, since this is the actual component-separation signal.
2. Reframe the central claim: the boundary is not simply 'animal-disease to aged-men' but specifically that isolated resveratrol lacked skeletal/metabolic efficacy in healthy aged men while combined resveratrol+exercise improved cardiac/aortic measures in an AD mouse model. State whether any direct contradiction or non-transfer is actually demonstrated.
3. Specify in limitations which of the listed axes (species, population health status, modality, endpoint class, dose, duration) Receipt 2's evidence does or does not control for, since Receipt 2 does control for exercise modality (endurance training) and dose (250 mg).
4. Provide a concrete falsifier that maps onto Receipt 2's actual design constraints (e.g., a matched aged-men study with the same 250 mg resveratrol dose and 8-week endurance protocol measuring cardiac/aortic endpoints, not just skeletal).

Major issues

• The memo frames Receipt 1 as supporting a 'combined-protocol cardiac/aortic signal' but the title/source alignment check requires that the named interventions in the title match the receipts. Receipt 1's title explicitly tests combined resveratrol + exercise in a mouse AD model, while Receipt 2 isolates exercise from resveratrol. The contrast is genuine but the memo overstates Receipt 2 as 'separating the components' — Receipt 2 actually shows combined exercise+resveratrol vs exercise alone vs resveratrol alone vs placebo, so it does isolate components. However, the memo's central claim that 'Receipt 2 separates the components and limits transfer to skeletal/metabolic in aged-men' conflates two findings: (a) resveratrol alone didn't improve skeletal muscle outcomes, and (b) the exercise effect was in skeletal muscle not cardiac/aortic. The 'boundary' claim is real but underexplained.
• The memo does not acknowledge that Receipt 2's abstract actually describes a combined arm (exercise + resveratrol) alongside isolated arms — meaning Receipt 2 also tests the combined protocol, and the comparison with Receipt 1 is more nuanced than 'combined vs separated.' This materially affects the receipt-role check stated in the memo.

Minor issues

• The title 'resveratrol exercise animal-disease-to-aged-men endpoint boundary' is descriptive but the memo could more clearly state the primary signal in the first sentence.
• Receipt 1 excerpts are truncated mid-sentence ('Late (A) ventricular filling ve'), making it harder to verify the cardiac/aortic claim, though the title supports it.
• Receipt 2 reports resveratrol had no effect alone but the abstract is truncated so whether resveratrol attenuated the exercise effect (interaction) cannot be verified from bundle — worth flagging.
• The 'Why this is surprising' section states the surprise is 'the receipt-owned boundary' but does not articulate what prior expectation it overturns — this weakens the novelty framing.

Reviewer note

The memo identifies a real cross-receipt contrast: combined resveratrol+exercise showed cardiac/aortic benefits in an AD mouse model (Receipt 1, 2019), while isolated resveratrol failed to improve skeletal muscle metabolic/inflammatory outcomes in healthy aged men (Receipt 2, 2014). However, the memo oversimplifies Receipt 2 by calling it a 'component-separating' study without acknowledging its four-arm design that includes a combined exercise+resveratrol arm. The 'boundary' framing is reasonable but underexplored — the memo does not engage with whether resveratrol alone failed in Receipt 2, whether it added to or attenuated exercise effects, or whether the contrast is truly one of model/population or one of endpoint class (cardiac/aortic vs skeletal). The limitations section lists relevant axes but does not specify which Receipt 2 controls. The falsifier and gap are directionally correct but loosely specified. Source grounding is solid — both DOIs and titles are accurate and match the cited claims. Revise is warranted because the component-isolation framing needs correction and the boundary claim needs sharper mechanistic specification.

Panel metadata

Models: MiniMax-M3 + google/gemma-4-31b-it + mistralai/mistral-small-2603

Route: fallback_tiebreak_failed_conservative

Prompt: reviewer-v11-research-synthesis